Questions about leptomeningeal metastasis
What is the response rate for intrathecal chemotherapy in lung cancer leptomeningeal metastasis?
Across studies, intrathecal chemotherapy for lung cancer leptomeningeal metastasis produces objective response rates of roughly 34.5% to 86.4%, with higher rates in some single-drug trials [2][8][7].
Full answer →Can pancreatic cancer patients with leptomeningeal metastasis survive for a long time?
Leptomeningeal metastasis from pancreatic cancer is rare and usually has a very short median survival of 1 to 2 months, but rare individual cases have lived longer with intensive treatment [1].
Full answer →Can intrathecal therapy improve neurological outcomes for leptomeningeal metastasis?
Intrathecal therapy can shrink tumors and ease neurological symptoms in some patients with leptomeningeal metastasis, but benefits vary widely and it is not a cure.
Full answer →How is EGFR-mutant lung cancer treated when it causes leptomeningeal metastasis?
For EGFR-mutant lung cancer that has spread to the lining of the brain (leptomeningeal metastasis), studies point to osimertinib, sometimes combined with bevacizumab, and pemetrexed as treatments linked to longer survival.
Full answer →Does using an Ommaya reservoir for intrathecal chemotherapy help leptomeningeal metastasis?
Intrathecal chemotherapy through an Ommaya reservoir is a standard way to treat leptomeningeal metastasis, and comparative evidence suggests it may improve disease control and survival versus repeated lumbar puncture [3][7].
Full answer →Does intrathecal chemotherapy improve survival for patients with leptomeningeal metastasis?
Intrathecal chemotherapy can shrink or stabilize leptomeningeal metastasis and may extend survival in some patients, but benefit varies by cancer type and the evidence is not uniform.
Full answer →